Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen V Liu

Showing results (161-170 of 187) with videos related to

Pageof 19
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2022
Correction: Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with NTRK Fusion-Positive Solid TumorsGeorge D Demetri, Filippo De Braud, Alexander Drilon, et al.
British Journal of Cancer|September 4, 2021
NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer typesChristian Rolfo, Alexander Drilon, David Hong, et al.
Cancer Discovery|November 30, 2018
A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105Alexander Drilon, Siqing Fu, Manish R Patel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2022
Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid TumorsGeorge D Demetri, Filippo De Braud, Alexander Drilon, et al.
Future Oncology (London, England)|November 2, 2023
Pralsetinib in patients with RET fusion-positive non-small-cell lung cancer: A plain language summary of the ARROW studyFrank Griesinger, Giuseppe Curigliano, Vivek Subbiah, et al.
Pharmacoepidemiology and Drug Safety|November 25, 2024
Determining Line of Therapy from Real-World Data in Non-Small Cell Lung CancerConnor B Grady, Wei-Ting Hwang, Joshua E Reuss, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 31, 2019
A Phase I/II Trial of Cetuximab in Combination with Interleukin-12 Administered to Patients with Unresectable Primary or Recurrent Head and Neck Squamous Cell CarcinomaElizabeth L McMichael, Brooke Benner, Lakhvir S Atwal, et al.
The Lancet. Oncology|June 12, 2021
Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 studyJustin F Gainor, Giuseppe Curigliano, Dong-Wan Kim, et al.
JTO Clinical and Research Reports|August 19, 2024
Characteristics of Long-Term Survivors With EGFR-Mutant Metastatic NSCLCWilliam Tompkins, Connor B Grady, Wei-Ting Hwang, et al.
JCO Global Oncology|August 22, 2022
The Armed Conflict and the Impact on Patients With Cancer in Ukraine: Urgent ConsiderationsChristian Caglevic, Christian Rolfo, Ignacio Gil-Bazo, et al.
Pageof 19

Showing results (161-170 of 187) with videos related to

Sort By:
Pageof 19
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2022
Correction: Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with NTRK Fusion-Positive Solid TumorsGeorge D Demetri, Filippo De Braud, Alexander Drilon, et al.
British Journal of Cancer|September 4, 2021
NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer typesChristian Rolfo, Alexander Drilon, David Hong, et al.
Cancer Discovery|November 30, 2018
A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105Alexander Drilon, Siqing Fu, Manish R Patel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2022
Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid TumorsGeorge D Demetri, Filippo De Braud, Alexander Drilon, et al.
Future Oncology (London, England)|November 2, 2023
Pralsetinib in patients with RET fusion-positive non-small-cell lung cancer: A plain language summary of the ARROW studyFrank Griesinger, Giuseppe Curigliano, Vivek Subbiah, et al.
Pharmacoepidemiology and Drug Safety|November 25, 2024
Determining Line of Therapy from Real-World Data in Non-Small Cell Lung CancerConnor B Grady, Wei-Ting Hwang, Joshua E Reuss, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 31, 2019
A Phase I/II Trial of Cetuximab in Combination with Interleukin-12 Administered to Patients with Unresectable Primary or Recurrent Head and Neck Squamous Cell CarcinomaElizabeth L McMichael, Brooke Benner, Lakhvir S Atwal, et al.
The Lancet. Oncology|June 12, 2021
Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 studyJustin F Gainor, Giuseppe Curigliano, Dong-Wan Kim, et al.
JTO Clinical and Research Reports|August 19, 2024
Characteristics of Long-Term Survivors With EGFR-Mutant Metastatic NSCLCWilliam Tompkins, Connor B Grady, Wei-Ting Hwang, et al.
JCO Global Oncology|August 22, 2022
The Armed Conflict and the Impact on Patients With Cancer in Ukraine: Urgent ConsiderationsChristian Caglevic, Christian Rolfo, Ignacio Gil-Bazo, et al.
Pageof 19